Diagnostics

CorePlus Collaborates with AIxMED Providing 100% QC on Bladder Cancer Detection with AI

SAN JUAN, Puerto Rico, Jan. 7, 2026 /PRNewswire/ -- CorePlus announced the implementation of AIxURO, a state-of-the-art software solution that…

9 hours ago

CorePlus Collaborates with AIxMED Providing 100% QC on Bladder Cancer Detection with AI

SAN JUAN, Puerto Rico, Jan. 7, 2026 /PRNewswire/ -- CorePlus announced the implementation of AIxURO, a state-of-the-art software solution that…

9 hours ago

CorePlus Collaborates with AIxMED Providing 100% QC on Bladder Cancer Detection with AI

SAN JUAN, Puerto Rico, Jan. 7, 2026 /PRNewswire/ -- CorePlus announced the implementation of AIxURO, a state-of-the-art software solution that…

9 hours ago

Alps Dx Launches to Modernize Oral Fluid Drug Testing Through Connected Pre-Analytical Automation

RICHMOND, Va., Jan. 7, 2026 /PRNewswire/ -- Alps Dx today announced its official launch as an innovative diagnostics tooling and…

9 hours ago

Alps Dx Launches to Modernize Oral Fluid Drug Testing Through Connected Pre-Analytical Automation

RICHMOND, Va., Jan. 7, 2026 /PRNewswire/ -- Alps Dx today announced its official launch as an innovative diagnostics tooling and…

9 hours ago

Alps Dx Launches to Modernize Oral Fluid Drug Testing Through Connected Pre-Analytical Automation

RICHMOND, Va., Jan. 7, 2026 /PRNewswire/ -- Alps Dx today announced its official launch as an innovative diagnostics tooling and…

9 hours ago

InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test

Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026…

9 hours ago

InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test

Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026…

9 hours ago

InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test

Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026…

9 hours ago

Baird Medical Secures Regulatory Approvals in Pakistan and Vietnam

NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a…

9 hours ago